Skip to main content
Kenji Fujita, MD, Cardiology, New Brunswick, NJ, Robert Wood Johnson University Hospital

KenjiPFujitaMD

Cardiology New Brunswick, NJ

Adult Congenital Heart Disease

Physician

Dr. Fujita is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fujita's full profile

Already have an account?

Education & Training

  • New York Presbyterian Hospital(Cornell Campus)/Coney Island Hospital
    New York Presbyterian Hospital(Cornell Campus)/Coney Island HospitalFellowship, Cardiovascular Disease, 2005 - 2008
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
  • Harvard Medical School
    Harvard Medical SchoolClass of 2000

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2005 - 2025
  • NY State Medical License
    NY State Medical License 2004 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Press Mentions

  • Atsena Therapeutics Announces Positive 6-Month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
    Atsena Therapeutics Announces Positive 6-Month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)April 25th, 2023
  • Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
    Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society MeetingFebruary 8th, 2023
  • Foundation Launching Its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes
    Foundation Launching Its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated GenesNovember 10th, 2022
  • Join now to see all

Hospital Affiliations